Kim HY - Search Results

1

Candida parapsilosis: A systematic review to inform the World Health Organization fungal priority pathogens list.

Asogan M, Kim HY, Kidd S, Alastruey-Izquierdo A, Govender NP, Dao A, Shin JH, Heim J, Ford NP, Gigante V, Sati H, Morrissey CO, Alffenaar JW, Beardsley J. Asogan M, et al. Among authors: kim hy. Med Mycol. 2024 Jun 27;62(6):myad131. doi: 10.1093/mmy/myad131. Med Mycol. 2024. PMID: 38935912 Free PMC article.

2

Nontuberculosis mycobacteria infections: would there be pharmacodynamics without pharmacokinetics?

Kim HY, Sintchenko V, Alffenaar JW. Kim HY, et al. Eur Respir J. 2019 Nov 28;54(5):1901508. doi: 10.1183/13993003.01508-2019. Print 2019 Nov. Eur Respir J. 2019. PMID: 31780456 Free article. No abstract available.

3

Challenging the management of drug-resistant tuberculosis.

Kim HY, Heysell SK, Mpagama S, Marais BJ, Alffenaar JW. Kim HY, et al. Lancet. 2020 Mar 7;395(10226):783. doi: 10.1016/S0140-6736(20)30049-0. Lancet. 2020. PMID: 32145792 No abstract available.

4

Optimal Dose or Optimal Exposure? Consideration for Linezolid in Tuberculosis Treatment.

Kim HY, Srivastava S, Ak HK, Marais BJ, Alffenaar JW. Kim HY, et al. Antimicrob Agents Chemother. 2020 Jun 23;64(7):e00287-20. doi: 10.1128/AAC.00287-20. Print 2020 Jun 23. Antimicrob Agents Chemother. 2020. PMID: 32366715 Free PMC article. No abstract available.

5

Saliva for Precision Dosing of Antifungal Drugs: Saliva Population PK Model for Voriconazole Based on a Systematic Review.

Kim HY, Märtson AG, Dreesen E, Spriet I, Wicha SG, McLachlan AJ, Alffenaar JW. Kim HY, et al. Front Pharmacol. 2020 Jun 12;11:894. doi: 10.3389/fphar.2020.00894. eCollection 2020. Front Pharmacol. 2020. PMID: 32595511 Free PMC article.

6

Therapeutic drug monitoring practice in patients with active tuberculosis: assessment of opportunities.

Kim HY, Ulbricht E, Ahn YK, Gillooly IS, Lee KJ, Lieu J, Nguyen W, Young S, Cho JG, Alffenaar JW. Kim HY, et al. Eur Respir J. 2021 Jan 28;57(1):2002349. doi: 10.1183/13993003.02349-2020. Print 2021 Jan. Eur Respir J. 2021. PMID: 32817005 Free article. No abstract available.

7

Saliva-based linezolid monitoring on a mobile UV spectrophotometer.

Kim HY, Ruiter E, Jongedijk EM, Ak HK, Marais BJ, Pk B, Sawleshwarkar S, Touw DJ, Alffenaar JW. Kim HY, et al. J Antimicrob Chemother. 2021 Jun 18;76(7):1786-1792. doi: 10.1093/jac/dkab075. J Antimicrob Chemother. 2021. PMID: 33734351

8

Therapeutic Drug Monitoring in Non-Tuberculosis Mycobacteria Infections.

Alffenaar JW, Märtson AG, Heysell SK, Cho JG, Patanwala A, Burch G, Kim HY, Sturkenboom MGG, Byrne A, Marriott D, Sandaradura I, Tiberi S, Sintchencko V, Srivastava S, Peloquin CA. Alffenaar JW, et al. Among authors: kim hy. Clin Pharmacokinet. 2021 Jun;60(6):711-725. doi: 10.1007/s40262-021-01000-6. Epub 2021 Mar 10. Clin Pharmacokinet. 2021. PMID: 33751415 Free PMC article. Review.

9

Therapeutic Drug Monitoring of the Echinocandin Antifungal Agents: Is There a Role in Clinical Practice? A Position Statement of the Anti-Infective Drugs Committee of the International Association of Therapeutic Drug Monitoring and Clinical Toxicology.

Kim HY, Baldelli S, Märtson AG, Stocker S, Alffenaar JW, Cattaneo D, Marriott DJE. Kim HY, et al. Ther Drug Monit. 2022 Feb 1;44(1):198-214. doi: 10.1097/FTD.0000000000000931. Ther Drug Monit. 2022. PMID: 34654030 Review.

10

Dosing of vancomycin and target attainment in neonates: a systematic review.

Alrahahleh D, Xu S, Luig M, Kim HY, Alffenaar JW. Alrahahleh D, et al. Among authors: kim hy. Int J Antimicrob Agents. 2022 Feb;59(2):106515. doi: 10.1016/j.ijantimicag.2021.106515. Epub 2022 Jan 11. Int J Antimicrob Agents. 2022. PMID: 35031450

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

6,774 results

Search Page

Filters